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ABSTRACT
Introduction: Recent developments in the care
of patients with idiopathic pulmonary fibrosis
have the potential to improve survival rates.
Population-based estimates of the current dis-
ease burden are needed to evaluate the future
impact of newly approved therapies. The
objective of this study is to describe incidence,
prevalence, and survival of idiopathic pul-
monary fibrosis patients in the UK.
Methods: Between 2000 and 2012, a patient
cohort (N = 9,748,108), identified from Clinical
Practice Research Datalink primary care data,
was used to identify incident and prevalent
cases of idiopathic pulmonary fibrosis–clinical
syndrome. Incident cases were followed up to
identify deaths. Poisson and Cox regressions
were used to calculate incidence rate ratios (IRR)
and hazard ratios for mortality, respectively.
Adjustments were made for age, gender, and
strategic health authority. Survival from diag-
nosis was estimated using Kaplan–Meier
analysis.
Results: In total 1491 and 4527 incident cases
were identified using narrow and broad idio-
pathic pulmonary fibrosis–clinical syndrome
definitions, respectively. Incidence and preva-
lence increased during the study. Compared
with 2000, a near 80% increase in incidence was
observed by 2012 [IRR 1.78 (95% CI 1.50–2.11;
broad definition)], despite an observed decrease
using the narrow definition [0.50 (0.38–0.65)].
Median survival was 3.0 years (95% CI 2.8–3.1)
and 2.7 years (95% CI 2.5–3.0) in broad
(n = 2168) and narrow case sets (n = 996),
respectively. No significant changes in survival
were observed.
Conclusions: Idiopathic pulmonary fibrosis
incidence rates have increased since 2000 and
survival remains poor. These results provide a
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INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a chronic,
progressive fibrotic interstitial lung disease (ILD)
of unknown etiology. The disease occurs pre-
dominantly inmiddle-aged and elderly adults, is
more frequent in men, and has been linked with
cigarette smoking and occupational exposure
[1, 2]. Prognosis for patientswith IPF is poor,with
median survival estimated to be around only
3–4 years [3–7]. Historically, treatment options
for patientswith IPF have been limited; however,
the UK has seen a number of important devel-
opments in the treatment of IPF, which it is
hoped will translate into improved patient out-
comes. These include the development of ILD
specialist services [8]; the licensing and reim-
bursement approval of antifibrotic therapy,
firstly pirfenidone in 2013 and nintedanib in
2015 [9, 10]; and publication of National Insti-
tute for Health and Care Excellence (NICE)
guidelines on the diagnosis and management of
suspected IPF [11]. If the impact of these impor-
tant developments in IPF care is to be measured,
it is vital that the underlying IPF disease burden is
understood.Moreover, the limited available data
on the epidemiologyof IPF, both in theUKand in
the USA [6, 12], suggest that the incidence [4, 5]
and mortality [5, 13, 14] rates, as well as hospi-
talizations [15], for IPF are increasing. Establish-
ing robust estimates of the underlying and
secular trends in the epidemiological burden of
IPF is therefore of increasing public health
significance.
METHODS
We carried out a population-based study using
data from 2000 to 2012, which aimed to
describe the incidence, prevalence, and survival
of patients with IPF in the UK, both overall and
stratified by calendar year, age, gender, and
strategic health authority. We use the term
IPF–clinical syndrome (IPF–CS) to describe
patients with IPF in our study in order to reflect
the imprecision of current coding terms. Owing
to the relatively recent introduction of recom-
mended standard diagnostic criteria for IPF [16],
and the potential for variability in diagnostic
coding, we used both broad and narrow defini-
tions for IPF–CS to explore the impact of coding
specificity on the chosen outcome measures.
Data Source
Data were obtained from the Clinical Practice
Research Datalink (CPRD) GOLD primary care
database (formerly the General Practice Research
Database, GPRD). The CPRD is a research and
data services provider in the UK, which brings
togetherdata fromacross theUKNationalHealth
Service and is jointly funded by the Medicines
and Healthcare products Regulatory Agency
(MHRA) and the National Institute for Health
Research [17]. CPRD GOLD is one of the largest
computerized databases of anonymized and
longitudinal electronic medical records in the
world. At the time of analysis, data were held for
approximately 14 million patients, around 5.4
million of whomwere alive and registered in 660
contributing general practices across theUK. The
data recorded include information on patient
demographics, clinical events and diagnoses,
details of specialist referrals, hospital admissions,
results of laboratory tests, and prescriptions
issued. Clinical events and diagnoses are recor-
ded via Read codes [18], and practices are
assigned an ‘‘up-to-standard’’ date, which indi-
cateswhen thedata recordedby that practicemet
pre-specified completeness criteria. Data in
CPRDGOLDare broadly representative of theUK
population [19] and the validity of the recorded
clinical data is considered to be high [20]. The
database has also been validated previously for
use in respiratory epidemiology [21]. The study
protocol was reviewed and approved by the
CPRD Independent Scientific Advisory Com-
mittee (reference number 13_083).
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Study Population and Follow-up
to Identify Cases of IPF–CS
The study population comprised all patients
registered for at least 1 day in practices con-
tributing data deemed ‘‘up-to-standard’’ by
CPRD GOLD between 1 January 2000 and 31
December 2012 (N = 9,748,108). Patients were
followed from their index date until the earliest
of the following: date of death, date of transfer
out of the practice, or date of last practice data
collection. Prevalent cases of IPF–CS were
identified on the basis of the presence of a rel-
evant Read code using our broad or narrow
definition of IPF–CS. Read codes included in our
narrow IPF–CS case definition were H563.00
(Idiopathic fibrosing alveolitis), H563.12
(Cryptogenic fibrosing alveolitis), H563z00
(Idiopathic fibrosing alveolitis NOS), H563300
(Usual interstitial pneumonitis), and H563.13
(Idiopathic pulmonary fibrosis). Our broad
IPF–CS definition included the following three
additional Read codes: H563100 (Diffuse pul-
monary fibrosis), H563200 (Pulmonary fibrosis),
and H563.11 (Hamman–Rich syndrome).
Patients with Read codes for connective tissue
disease, extrinsic allergic alveolitis, sarcoidosis,
pneumoconiosis, or asbestosis (Table S1) at any
time in their medical records were not included
as cases. Incident cases of IPF–CS were identified
by applying the following eligibility criteria to
the prevalent cases: at least 1 year of registration
with their general practitioner, at least 1 year of
up-to-standard data in their patient records
before the index date, and no Read code for
IPF–CS prior to the start of the study period (1
January 2000).
Statistical Analysis
Incidence and prevalence of IPF–CS per
100,000 patient-years were estimated along
with 95% confidence intervals (CIs) calculated
using the Poisson distribution. Incidence rates
were calculated by dividing the number of
incident cases by the total person-time contri-
bution, and were calculated both overall and
stratified by calendar year, gender, 5-year age
group, and strategic health authority. Poisson
regression modelling was used to estimate
annual incidence rate ratios (IRRs), controlling
for age, sex, and strategic health authority.
Multiplicative interaction terms were applied to
test for potential effect modification by age and
sex. Point prevalence of IPF–CS was calculated
for each calendar year in the study period. The
numerator was the number of patients with a
specified Read code for IPF–CS prior to the
midpoint of the year of interest, and the
denominator was the number of patients in the
study population at the midpoint of the year of
interest. Prevalence ratios for 2012 were addi-
tionally stratified by age group, gender, and
strategic health authority.
Life table analysis was carried out to estimate
cumulative mortality (with 95% CIs) at 48 weeks,
52 weeks, 60 weeks, 72 weeks, 3 years, 5 years,
10 years, and more than 10 years after incident
diagnosis. Survival was analyzed using Kaplan–-
Meiermethods, both overall and stratified by year
of diagnosis, gender, 5-year age group, and
strategic health authority. Cox regression analysis
was performed to calculate hazard ratios adjusted
for all other covariates, and to test for interactions
betweenmortality rates and year of diagnosis, age
group, gender, and strategic health authority. The
following reference categories were used in these
analyses, respectively: (1) patients diagnosed in
2000; (2) patients aged 65–69; (3) male patients;
(4) patients based in the North West Strategic
Health Authority. Patients were censored in the
Kaplan–Meier and Cox regression analyses
according to the date they left the practice or the
last date that the practice contributed data to
CPRD prior to analysis. Statistical analyses were
performed using Stata version 12.0 (StataCorp LP,
College Station, TX, USA).
Compliance with Ethics Guidelines
This article reports a population-based cohort
study and does not contain any studies with
human participants or animals performed by
any of the authors.
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RESULTS
Incidence and Prevalence of IPF–CS
The total number of incident cases of IPF–CS
identified between 2000 and 2012 was 1491
using our narrow case definition, and 4527
using our broad case definition. These cases
were identified over a total follow-up period of
52,355,644 and 52,341,029 years, respectively.
Overall and stratified incidence rates of IPF–CS
and IRRs are shown in Figs. 1 and 2. The overall
incidence rate per 100,000 patient-years was
2.85 (95% CI 2.71–3.00) using the narrow case
definition and 8.65 (8.40–8.90) for the broad
case definition. Incidence of IPF–CS increased
with age, was more common in male patients
than female patients, and varied across regions
(as assessed by strategic health authority);
being highest in the North West region and
Northern Ireland, and lowest in the South East.
When using a broad IPF–CS case definition,
Fig. 1 Adjusted incidence rate ratios of IPF–CS stratiﬁed
by calendar year using a narrow deﬁnition and b broad
deﬁnition. CPRD, Clinical Practice Research Datalink;
IPF–CS, idiopathic pulmonary ﬁbrosis clinical syndrome.
All incidence rate ratios are mutually adjusted for other
variables: gender, age group, and strategic health authority
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mutually adjusted IRRs significantly increased
over the study period. Compared with the year
2000, a 78% increase in the incidence of
IPF–CS was observed in 2012 (IRR 1.78, 95% CI
1.50–2.11). No statistically significant interac-
tions (0.55\ p\0.74) were observed to suggest
the annual increase in incidence varied by age
or gender for either IPF–CS definition. Annual
prevalence is shown in Fig. 3. When the broad
case definition was used, prevalence of IPF–CS
approximately doubled over the study period;
starting at 19.94 per 100,000 patients (95% CI
18.48–21.47) in 2000 and rising to 38.82 per
100,000 patients (95% CI 37.04–40.66) in
2012. Prevalence in 2012 was higher in male
patients, increased with age, and varied across
strategic health authority, with highest rates in
Scotland and lowest rates in the South East
Coast (Fig. 3).
Mortality and Survival of Patients
with IPF–CS
Among incident cases, a total of 2618 and 996
deaths occurred over 11,468 and 4167 years of
follow-up from diagnosis in broad and narrow
case sets, respectively. Similar patterns of sur-
vival were observed with both narrow and broad
case definitions (Table 1). Median survival was
3.0 years (95% CI 2.80–3.10) in the broad case
group and 2.7 years (95% CI 2.5–3.0) in the
narrow case group. Half of patients were alive at
3 years following IPF–CS diagnosis using our
broad case definition; 5- and 10-year survival
rates were 34% and 19%, respectively. There
was no statistically significant survival differ-
ence between the broad and narrow case
groups, log rank test p = 0.06 (Fig. 4a). There
was no statistically significant difference in the
Fig. 2 Crude incidence rates of IPF–CS stratiﬁed by a calendar year, b gender, c age, and d strategic health authority.
CPRD, Clinical Practice Research Datalink; IPF–CS, idiopathic pulmonary ﬁbrosis clinical syndrome; Yorks, Yorkshire
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survival function by year of diagnosis, log rank
test p = 0.17 (broad case definition; Fig. 4b).
Models adjusted for demographic variables
show that patients diagnosed in 2000 had a
higher mortality rate than patients diagnosed in
later years (Table 2). However, there is no clear
evidence of improvement over time. There was
no statistically significant interaction between
age and gender following further adjustments
(0.07\ p\0.75).
DISCUSSION
Our large population-based study provides
national estimates of the epidemiological bur-
den of IPF in the UK. We did not observe any
improvements in survival from diagnosis in
patients with IPF–CS over our relatively recent
study period (2000–2012). Overall, median sur-
vival was found to be 3 years, consistent with
rates from previous studies [3, 5] and similar,
albeit slightly lower, than that reported by other
groups [4, 6, 7]. Navaratnam et al. [5] found that
median survival did not change significantly in
the UK between 2000 and 2008 using data from
The Health Improvement Network (THIN), a
primary care database similar to CPRD GOLD.
They also reported 5-year survival to be 37%,
similar to our value of 34%. Gribbin et al. [4]
also investigated mortality of IPF using data
from THIN, and reported a 5-year survival rate
of 43% over their earlier study period.
Fig. 3 Prevalence rates of IPF–CS stratiﬁed by a calendar
year, b gender, c age, and d strategic health authority.
CPRD, Clinical Practice Research Datalink; IPF–CS,
idiopathic pulmonary ﬁbrosis clinical syndrome; Yorks,
Yorkshire. ‘‘[a]’’ For this analysis the lower age groups
(0–39 and 40–44) and two regions (Yorkshire & The
Humber and North East) have been combined in line with
CPRD policy on low cell counts
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When a broad case definition was used, the
incidence of IPF–CS increased over time and was
found to have risen almost 80% over the course
of our study period. This trend of rising inci-
dence is in line with reports from previous
studies carried out in the UK using data from
primary care [4, 5] and hospital admissions [15].
However, when a narrow case definition was
used, an overall decrease in incidence over time
was observed. This observation is likely due to
changes in the availability of Read codes and
recording practices over time. Alternatively, this
contrasting trend could be explained by the fact
that the overall number of incident cases
recorded using the narrow definition is consid-
erably lower than those recorded using the
broad definition (1491 and 4527 cases, respec-
tively). There is also a possibility that the diag-
nostic precision used to distinguish IPF from
other types of fibrotic lung disease may have
increased over the course of the study period.
We found the incidence of IPF–CS to
increase with age and to be higher in male
patients, consistent with other reports from the
UK and the USA [4–6, 22], but found no evi-
dence that the increase in incidence over time
was restricted to, or significantly varied by, age
group or gender. Findings from others regarding
such age and gender effects have been mixed
[4, 5, 15]. Our estimates of IPF–CS occurrence
and survival were adjusted by age group, sex,
and health authority, thus suggesting that the
Table 1 Mortality rates using narrow and broad IPF–CS case deﬁnitions
Interval since
index date
Number of patients
alive at beginning of
interval
Deaths
during
interval
Number of patients
censored during
interval
Cumulative
survival (95%
CI)
Cumulative
mortality (95%
CI)
Narrow IPF–CS case deﬁnition
0–48 weeks 1491 383 95 0.73 (0.71–0.76) 0.27 (0.24–0.29)
48–52 weeks 1013 26 7 0.72 (0.69–0.74) 0.28 (0.26–0.31)
52–60 weeks 980 41 20 0.69 (0.66–0.71) 0.31 (0.29–0.34)
60–72 weeks 919 41 21 0.65 (0.63–0.68) 0.35 (0.32–0.37)
72 weeks–3 years 857 219 83 0.48 (0.45–0.51) 0.52 (0.49–0.55)
3–5 years 555 171 97 0.32 (0.29–0.34) 0.68 (0.66–0.71)
5–10 years 287 110 138 0.16 (0.13–0.18) 0.84 (0.82–0.87)
[ 10 years 39 5 34 0.12 (0.09–0.16) 0.88 (0.84–0.91)
Broad IPF–CS case deﬁnition
0–48 weeks 4527 1090 413 0.75 (0.73–0.76) 0.25 (0.24–0.27)
48–52 weeks 3024 54 43 0.73 (0.72–0.75) 0.27 (0.25–0.28)
52–60 weeks 2927 100 83 0.71 (0.69–0.72) 0.29 (0.28–0.31)
60–72 weeks 2744 117 105 0.68 (0.66–0.69) 0.32 (0.31–0.34)
72 weeks–3 years 2522 611 435 0.50 (0.48–0.51) 0.50 (0.49–0.52)
3–5 years 1476 402 379 0.34 (0.33–0.36) 0.66 (0.64–0.67)
5–10 years 695 231 383 0.19 (0.17–0.20) 0.81 (0.80–0.83)
[ 10 years 81 13 68 0.13 (0.11–0.16) 0.87 (0.84–0.89)
CI conﬁdence interval, IPF–CS idiopathic pulmonary ﬁbrosis clinical syndrome
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observed increase in incidence and survival is
unlikely due to demographic changes in the UK
population over time. Other explanations
should nevertheless be considered. For instance,
it is possible that changes in disease ascertain-
ment and recording of IPF–CS could explain
some of the observed rise in incidence. Given
that improvements in ascertainment should
result in the detection of milder cases, such an
explanation is compatible with the changing,
albeit inconsistent, survival found using both
narrow and broad case definitions. Further-
more, the widely heralded publication of inter-
national evidence-based guidelines on the
diagnosis and management of IPF in 2011 [23]
may explain the slightly greater increase in
incidence observed in 2012 due to heightened
physician awareness, as might the approval in
Europe of pirfenidone in March 2011.
We found regional variation in the incidence
of IPF–CS across the UK, with highest rates in
the North West and Northern Ireland, and
lowest rate in the South East (using the broad
case definition), consistent with findings by
Navaratnam et al. [5]. In their earlier study
period, Gribbin et al. [4] also found rates to be
lowest in the South East, but high rates were
reported for Scotland in addition to the North
West. This regional variation may reflect geo-
graphical differences in environmental and
occupational risks and is likely to have impor-
tant implications for national resource utiliza-
tion. Our study also highlights the impact of
using different diagnostic codes for IPF on esti-
mates of incidence and prevalence. The
observed similarity in patterns of survival when
using either narrow or broad case definitions
suggests that both sets of Read codes capture a
similar range of cases across disease severity.
The similarity of outcomes seen in both groups,
when compared to well-defined cohorts of
patients with IPF identified through tertiary
centers, suggests that the chosen diagnostic
codes are successfully identifying patients with
disease conforming to the internationally
accepted criteria for a diagnosis of IPF.
Fig. 4 Kaplan–Meier survival analysis for all incident cases of IPF–CS a using broad and narrow case deﬁnitions, b by year
of diagnosis using the broad case deﬁnition
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Table 2 Relative effect of calendar year of diagnosis,
gender, age group, and strategic health authority on risk of
mortality using narrow and broad IPF–CS case deﬁnitions
Mutually adjusted HRs (95%
CI)
Narrow IPF–CS case deﬁnition
Year
2000 1
2001 0.72 (0.54–0.96)
2002 0.9 (0.69–1.19)
2003 0.94 (0.71–1.23)
2004 0.74 (0.57–0.97)
2005 0.81 (0.61–1.07)
2006 0.67 (0.5–0.91)
2007 0.75 (0.54–1.02)
2008 0.71 (0.51–0.99)
2009 0.58 (0.38–0.89)
2010 0.74 (0.49–1.1)
2011 0.51 (0.3–0.88)
2012 0.73 (0.45–1.16)
Gender (2012)
Male 1
Female 0.79 (0.69–0.91)
Age (years) (2012)
0–39 0.58 (0.18–1.86)
40–44 0.45 (0.11–1.85)
45–49 0.09 (0.01–0.63)
50–54 0.41 (0.23–0.75)
55–59 0.47 (0.28–0.78)
60–64 0.94 (0.71–1.25)
65–69 1
70–74 1.33 (1.07–1.66)
80–84 1.55 (1.25–1.93)
85–89 2.06 (1.64–2.59)
C 90 2.17 (1.67–2.81)
Strategic health authority (2012)
North East 1.13 (0.68–1.89)
North West 1
Yorks and The Humber/North
East
0.95 (0.68–1.32)
East Midlands 0.84 (0.61–1.17)
West Midlands 1.23 (0.94–1.62)
East of England 1 (0.76–1.3)
South West 0.96 (0.73–1.26)
South Central 1 (0.76–1.31)
London 0.94 (0.72–1.24)
Table 2 continued
Mutually adjusted HRs (95%
CI)
South East Coast 0.87 (0.66–1.15)
Northern Ireland 0.75 (0.45–1.26)
Scotland 1.01 (0.76–1.35)
Wales 0.95 (0.73–1.24)
Broad IPF–CS case deﬁnition
Year
2000 1
2001 0.75 (0.60–0.93)
2002 0.89 (0.72–1.10)
2003 0.82 (0.67–1.01)
2004 0.73 (0.60–0.89)
2005 0.76 (0.62–0.93)
2006 0.77 (0.63–0.95)
2007 0.74 (0.60–0.91)
2008 0.73 (0.59–0.90)
2009 0.66 (0.53–0.82)
2010 0.71 (0.57–0.89)
2011 0.71 (0.57–0.90)
2012 0.61 (0.47–0.79)
Gender (2012)
Male 1
Female 0.72 (0.66–0.78)
Age (years) (2012)
0–39 0.32 (0.14–0.72)
40–44 0.27 (0.11–0.66)
45–49 0.37 (0.20–0.70)
50–54 0.41 (0.28–0.61)
55–59 0.59 (0.44–0.78)
60–64 0.85 (0.70–1.02)
65–69 1
70–74 1.25 (1.07–1.44)
80–84 1.48 (1.28–1.70)
85–89 1.89 (1.64–2.18)
C 90 2.36 (2.02–2.76)
Strategic Health Authority (2012)
North East 1.04 (0.78–1.40)
North West 1
Yorks and The Humber/North
East
0.90 (0.72–1.12)
East Midlands 0.91 (0.73–1.13)
West Midlands 1.14 (0.98–1.34)
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Our study has several strengths. The large
size of the CPRD cohort provided a representa-
tive snapshot of the UK population and the
long study period enabled ascertainment of
precise estimates of disease occurrence, mortal-
ity, and temporal change. The use of the CPRD
GOLD database enabled analysis of the large
dataset required to attempt to estimate the
epidemiological burden of IPF; however, we
recognize that the main potential weakness of
our study concerns the validity of the IPF
diagnosis.
Case ascertainment was based on diagnostic
coding used by general practitioners in primary
care, rather than standard diagnostic criteria.
We accept that there is a possibility of misclas-
sification of IPF [19]. Unfortunately, it was not
possible to validate the diagnostic coding
because of the large quantity of data, but lim-
ited informal re-evaluation suggested that sub-
jects did indeed have IPF. In a previous study
evaluating IPF using data from the GPRD,
Hubbard et al. [24] found the validity of IPF
diagnoses in the database to be high; 95% of
identified cases were found to be true positives.
Furthermore, IPF can be difficult to diagnose,
with patients usually only identified in sec-
ondary, or even tertiary, centers by multidisci-
plinary teams experienced in the diagnosis of
ILD. We therefore believe that it is unlikely that
a general practitioner would record a diagnosis
of IPF without having received notification
from a respiratory specialist in secondary care.
The similar pattern in survival seen over time
using both narrow and broad case definitions in
our study also supports the validity of the
IPF–CS diagnosis in our cases. With regards to
case ascertainment, we feel that it is unlikely
that many cases in the community would have
been missed. This is because patients with IPF
suffer chronic and progressive exertional dysp-
nea and cough for which they usually seek
medical attention [1]. However, under-ascer-
tainment of cases in our study is possible owing
to the reliance on the transfer of information
between secondary and primary care, and so
some cases diagnosed in secondary care may
have been missed. Another limitation is the
possibility that some incident cases were mis-
classified and were actually prevalent cases. This
would not have affected the observed trends in
increased incidence or survival over time, but
may have overestimated survival because
prevalent cases have greater average survival
than incident cases [3].
It should also be noted that a considerable
proportion of patients were lost to follow-up
(22% and 32% of patients in the narrow and
broad definitions, respectively, over the first
5 years after diagnosis). Follow-up time for the
incidence analysis was slightly lower using the
broad definition than the narrow definition, as
patients would have been identified as preva-
lent IPF patients at study initiation (using the
broad definition) and were therefore excluded
from the analysis. In some cases, censoring of
patients may be linked to disease outcome; for
example, IPF patients are more likely to move to
a nursing home and change to another general
practice prior to death, which would lower the
estimated mortality rate.
CONCLUSIONS
This study provides estimates of the epidemio-
logical burden of IPF in the UK. Our finding that
the survival of patients with IPF–CS is very poor
and has changed little over recent years
undoubtedly reflects the lack of effective treat-
ments available to patients with this devastating
Table 2 continued
Mutually adjusted HRs (95%
CI)
East of England 0.87 (0.74–1.02)
South West 0.93 (0.80–1.09)
South Central 1.08 (0.92–1.26)
London 0.85 (0.72–1.01)
South East Coast 0.95 (0.81–1.12)
Northern Ireland 0.86 (0.69–1.07)
Scotland 0.96 (0.82–1.12)
Wales 0.87 (0.74–1.02)
Data from 2012 were used to calculate hazard ratios for gender, age, and
strategic health authority
HR hazard ratio, CI conﬁdence interval, CPRD Clinical Practice Research
Datalink, IPF–CS idiopathic pulmonary ﬁbrosis clinical syndrome
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disease during this time period. The antifibrotic
therapies pirfenidone, in 2013, and nintedanib,
in 2015, have been approved for reimbursement
in the UK by NICE for the treatment of adults
with mild-to-moderate IPF. Since then pir-
fenidone has been shown, in a clinical trial set-
ting, to reduce disease progression and to
improve survival [25–27]. Whether the use of
antifibrotic therapies [28] translates into
increased survival in real-world patients with IPF
will need to be evaluated in coming years. Elec-
tronic medical records, such as those in CPRD
GOLD, constitute valuable data sources for the
evaluation of IPF. Unlike CPRD GOLD, disease
registries inmost countries are limited by the fact
that registration of IPF is not mandatory and
therefore inclusion of cases is open to bias.
The results of this study provide an impor-
tant benchmark against which the effects of
changes in the management and treatment of
IPF can be measured, and thereby lays the
foundation for further research.
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